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Abstract 
Introduction: Corticosteroids are steroid hormones synthesized and secreted by the adrenal 
gland that modulate a wide range of physiological processes, including stress response, immune-
inflammatory response, carbohydrate and protein catabolism, blood electrolyte levels, and 
behaviour. Topic corticosteroids are more frequently used in the dental practice, generally 
focusing on the symptomatic management of oral mucosa conditions.  
Objective: This work is set on the clinical use of topical corticosteroids in dental practice, 
namely for the management of oral mucosal conditions,  embracing the indications, 
contraindications, advantages and disadvantages of their use, as well as the different forms of 
administration (use of adhesive ointments, gels, intra-lesion injections, customized tray) and 
therapeutic regimens, for the optimizations of the clinical output. 
Material and Methods: The search for relevant references and articles was conducted in the 
PubMed and Scopus databases. The following combination of keywords was used: topical 
corticosteroids, corticosteroids, systemic corticosteroids, glucocorticoids, topical glucocorticoids, 
systemic glucocorticoids, treatment guidelines, pregnancy, oral pathology, dental medicine, oral 
mucosa, oral lichen planus, pemphigous, pemphigoid, recurrent aphthous stomatitis. Mainly 
review articles, research articles, clinical trials and case reports were selected, which publication 
date was comprehended between 2005 and 2016. Only papers in Portuguese or English, with 
access to the full text were chosen, according to their relevance to the theme to describe. 
Following, each article was evaluated for inclusion by its content analysis. 
Conclusion: Guidelines for treatment / maintenance of distinct conditions with topical 
corticosteroid therapy were found available, especially regarding oral lichen plan and recurrent 
aphthous stomatitis conditions. However, less is known regarding therapeutic management of 
pemphigus vulgaris or bullous pemphigoid, since the majority of the literature refers to 
dermatology guidelines. As absorption by the skin is not as the one in oral mucosa, more studies 
should be conducted in these areas in order to disclose therapeutic guidelines adequately focused 
on the oral management of these conditions.    
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Resumo 
Introdução: Os corticosteróides são hormonas esteróides sintetizadas e secretadas pela glândula 
supra-renal que modulam uma vasta variedade de processos fisiológicos, incluindo a resposta ao 
stress, a resposta imuno-inflamatória, hidratos de carbono, o catabolismo de proteínas e 
carbohidratos, níveis de electrólitos no sangue, e o comportamento. Os corticosteróides tópicos 
são os mais frequentemente usados em Medicina Dentária, focando-se principalmente na gestão 
sintomática das lesões da mucosa oral.  
Objetivos: Este trabalho tem como objetivo rever na literatura atual o uso clínico de 
corticosteróides tópicos em prática de Medicina Dentária, ou seja, como abordagem terapêutica 
de algumas condições da mucosa oral, descrevendo as indicações, contra-indicações, vantagens e 
desvantagens da sua utilização, bem como as diferentes formas de administração (pomadas e 
géis adesivos, injeções intra-lesão, goteira individualizada) e regimes terapêuticos, para a 
optimização do tratamento. 
Material e Métodos: Foi efetuada uma pesquisa nas bases de dados da Pubmed e Scopus, por 
artigos e referências relevantes. A seguinte combinação de palavras-chave foram usadas: “topical 
corticosteroids, corticosteroids, systemic corticosteroids, glucocorticoids, topical glucocorticoids, 
systemic glucocorticoids, treatment guidelines, pregnancy, oral pathology, dental medicine, oral 
mucosa, oral lichen planus, pemphigous, pemphigoid, recurrent aphthous stomatitis”. 
Maioritariamente artigos de revisão e investigação, ensaios e casos clínicos foram selecionados, 
com datas de publicação entre 2005 e 2016. Apenas artigos em português e inglês, com acesso 
ao texto completo e com relevância para o tema a descrever foram selecionados. Seguidamente, 
cada artigo foi avaliado pela análise do seu conteúdo. 
Conclusão: Foram encontradas disponíveis guidelines relativas à aplicação tópica de 
corticosteróides, nomeadamente para o líquen plano oral e estomatite aftosa recorrente. No 
entanto, a abordagem terapêutica do pênfigo vulgar ou penfigóide bolhoso na Medicina Dentária 
não é clara, já que a maioria da literatura se refere a guidelines de dermatologia. Como a 
absorção pela pele não é como a da mucosa oral, mais estudos devem ser realizados no sentido 
de adequar as guidelines terapêuticas para as manifestações clínicas destas doenças na cavidade 
oral. 
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Introduction 
 
Corticosteroids are steroid hormones synthesized and secreted by the adrenal gland that 
modulate a wide range of physiological processes, including stress response, immune-
inflammatory response, carbohydrate and protein catabolism, blood electrolyte levels, and 
behaviour. (1, 2)  Synthetic analogues can be produced and of clinical relevance for the 
modulations of distinct conditions. However, side effects are common and potentially 
problematic, such as the development of diabetes mellitus, hypertension, osteoporosis, weight 
gain, cataracts, Cushing syndrome, among others. (1, 3)  These effects depend on the dose, 
duration of the treatment, rout of administration (for example: topic or systemic), among other 
factors. (1, 2)  
In dental practice the use of corticosteroids for a long period of time is not very common, which 
carries lower risks for the development of chronic use-related complications. (4)  Systemic 
corticosteroids are sometimes used following dental surgery (for instance for the management of 
the inflammatory response and edema formation associated with osteotomy). (5) Topic 
corticosteroids are more frequently used in the dental practice, generally focusing on the 
symptomatic management of oral mucosa conditions.  
 Oral local adverse reactions associated with topical corticosteroid therapy include secondary 
candidosis, mucosal atrophy, delayed cicatrization, refractory response, hypogeusia, burning 
mouth, hypersensitive reactions. (1, 2) Systemic adverse effects may include the inhibition of the 
hypothalamic-pituitary adrenal axis and secondary adrenal insufficiency, however these 
reactions only manifest in a small number of patients. (2)  
This work is set on the clinical use of topical corticosteroids in dental practice, namely for the 
management of oral mucosal conditions,  embracing the indications, contraindications, 
advantages and disadvantages of their use, as well as the different forms of administration (use 
of adhesive oinments, gels, intra-lesion injections, costumized tray) and therapeutic regimens, for 
the optimizations of the clinical output. 
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Material and methods 
 
The search for relevant references and articles was conducted in the PubMed and Scopus 
databases. The following combination of keywords was used: topical corticosteroids, 
corticosteroids, systemic corticosteroids, glucocorticoids, topical glucocorticoids, systemic 
glucocorticoids, treatment guidelines, pregnancy, oral pathology, dental medicine, oral mucosa, 
oral lichen planus, pemphigous, pemphigoid, recurrent aphthous stomatitis. Mainly review 
articles, research articles, clinical trials and case reports were selected, which publication date 
was comprehended between 2005 and 2016. Only papers in Portuguese or English, with access 
to the full text were chosen, according to their relevance to the theme to describe. Following, 
each article was evaluated for inclusion by its content analysis. 
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Glucocorticoids  
 
Steroids were identified in the 1940’s and since then, synthetic analogues have served a large 
range of uses, being applied for the management of inflammatory disorders, autoimmune 
diseases, antenatal use for preterm birth, and hematological cancers, among others. (6-8) Despite 
the huge advances in medicine since their discovery, a fully understanding of glucocorticoid 
action in physiological processes, such as inflammation, remains to be completely disclosed. (9) 
The term steroid can be applied to a plenteous variety of molecules which have different 
physiological effects. (8) Corticosteroids are a class of chemicals that include laboratory-
synthesized and naturally produced hormones. (8) Corticosteroids include agents that have effects 
that can be uniquely glucocorticoid to uniquely mineralocorticoid. The first are responsible for 
the regulation of metabolism and inflammation, whereas mineralocorticoids regulate, essentially, 
sodium and water levels and excretion. The prescription of a steroid compound may have potent 
anti-inflammatory effects and additionally mineralocorticoid activity, which can cause 
significant adverse effects such as hyponatremia, hyperkalemia and hypotension, or the inverse, 
in mineralocorticoid excess states. (8, 10)   
Glucocorticoids are catabolic steroid hormones synthesized and secreted by the adrenal gland as, 
among others, a response to stress. (7, 8, 10, 11)  
The adrenal cortex is composed of 3 cellular zones, each one synthesizing a specific class of 
steroid hormones, i.e. mineralocorticoids, glucocorticoids and androgens, as seen in figure 1. (4) 
The principal mineralocorticoid is aldosterone (involved in the regulation of sodium and water 
levels) which is controlled by the angiotensin pathway; the principal glucocorticoid is cortisol, 
responsible for many physiological functions and metabolism regulation. (4, 10) 
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Figure 1: Transverse and microscopic sections of the adrenal cortex. Each one synthesizes a specific class of 
steroid hormones: glomerulosa zone secretes essentially, the mineralocorticoid aldosterone, fasciculada zone 
broadly synthesizes the glucocorticoid cortisol, and reticular zone broadly produces adrogens (45) 
 
 
The release of steroids is regulated by an hormonal interplay system: stress conditions, 
hypoglicemia or trauma can stimulate hypothalamus to secret corticotrophin-releasing hormone 
(CRH), which acts on the anterior pituitary gland to induce the synthesis of adrenocorticotropic 
hormone (ACTH), also known by corticotropin. In turn, this hormone acts on the adrenal cortex 
to stimulate the secretion of glucocorticoids (cortisol). (4, 7) This secretion is in a direct response 
to the action of ACTH. (10) Cortisol, as well as exogenous glucocorticoids, provide negative 
feedback on CRH release from the hypothalamus, and consequently on ACTH (fig.2). (10) 
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Figure 2: Mechanism of cortisol secretion and negative feedback regulation. (Adapted from Daniel E.Becker, 
2013) (4) 
 
Glucocorticoids induce a variety of responses in virtually every tissue; in fact, they are important 
in metabolism, circadian rhythm, cell growth, reproduction and immunity. (12, 13) The 
mechanisms of glucocorticoids’ actions are far more diverse and complex than previously 
thought, although most effects are known to be mediated by the glucocorticoid receptor. (12, 13) In 
the 1950’s, it was found for the first time that cortisol can induce anti-inflammatory effects. 
Recent studies showed that physiological levels of glucocorticoids modulate inflammation and 
the immune functions, preventing excessive activation immune-inflammatory activation. (4) 
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The inflammatory response 
 
The inflammatory response is a physiological process that aims to restore tissue homeostasis. (14) 
The acute inflammation mechanisms are well understood. (15) Briefly, during an inflammatory 
response, exogenous or endogenous stimuli activate the tissue-resident macrophages, causing the 
release of inflammatory mediators, such as pro-inflammatory cytokines - tumour necrosis factor-
alpha (TNF-α), prostaglandin E2, interleukin 1 (IL-1) and interleukin 6 (IL-6). (15-17) The 
inflammatory process characterizes itself by vascular dilation, increased blood flow, enhanced 
permeability of capillaries and leukocyte recruitment (in which polymorphonuclear neutrophils 
are the first recruited non-resident populations to the inflamed local; followed by mononuclear 
cells, monocytes and macrophages, that clear the cellular debris and phagocyte the apoptotic 
neutrophils). (17) The resolution of acute inflammation must be efficient, or neutrophil-mediated 
destruction, fibrosis or chronic inflammation may develop. (14, 17)  
 
 
Glucocorticoids’ anti-inflammatory activity 
 
The anti-inflammatory activity of glucocorticoids is ascribed to the repression of pro-
inflammatory genes (e.g., chemokines, adhesion molecules, receptors, cytokines, etc.) over 
signal transduction, by the glucocorticoid receptor (steroid receptor). (7, 12) Glucocorticoids are 
lipophilic, which gives them the ability to pass across cell membranes easily. Then, they bind to 
their specific intracellular receptor (glucocorticoid receptor), located in the cytoplasm, resulting 
in conformational changes, phosphorylation, dimerization and activation of the same. (11, 18)  The 
binding is regulated by intracellular enzymes, being that the best described are the two types of 
11β-hydroxysteroid dehydrogenases (type 1 - 11β-HSD1; type 2 - 11β-HSD2), that can convert 
glucocorticoids in active or inactive forms. (18) Type 1 converts cortisone (inactive form) in 
cortisol (active form) and is expressed in the liver, muscle, pancreas, adipose tissue, bone and 
other tissues related to energy and metabolism; whereas type 2 inactivates cortisol and 
corticosterone (active forms) in cortisone and  dehydrocorticosterone, respectively (inactive 
forms), and its expression is limited to cells involved in sodium homeostasis, like kidney, colon, 
sweat and salivary glands. (18) Next, the complex receptor-steroid migrates into the nucleus, 
binding to DNA, altering the genetic synthesis of proteins. (4) In consequence, cellular functions 
are modified: reduction of the production of enzymes responsible for regulating the synthesis of 
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inflammatory autacoids and immune-related cytokines, prostaglandins inhibition (which 
contributes to their analgesic effect), among others. (4, 5) All these effects converge to the 
suppression of vascular changes (which are accountable for the cardinal signs of inflammation). 
(4) 
The glucocorticoid receptor can regulate gene expression positively or negatively. They can bind 
to palindromic glucocorticoid response elements (GREs) in the promoters of target genes or 
interact with other transcription factors, such as nuclear factor κB (NF-κB ), or activator protein-
1 (AP-1). (12) 
MAPKs (Mitogen – activated protein kinases) are signalling proteins capable of using the 
extracellular stimuli as a mean of activation of the intracellular transduction pathways, via 
phosphorylation of a cascade of substrates. They regulate various physiologic cell processes, 
such as proliferation, apoptosis, development, differentiation, etc. If inappropriately activated by 
extracellular stimuli (for instance lipopolysaccharide, pro-inflammatory cytokines, cellular 
stress, among others), these induce the expression of inflammatory genes, perpetuating 
inflammation. In mammals, at least 4 subfamilies of MAPKs are known: extracellular signal-
regulated kinases (ERKs), c-Jun NH2-terminal kinases (JNKs), p38 isoforms (p38s) and (ERK5). 
(12) 
Glucocorticoids can exert their anti-inflammatory effects by interfering negatively with MAPKs 
signalling pathways. MAPKs activate inflammatory cells and mediators in lymphocytes, 
macrophages, neutrophils and mast cells; in these inflammatory cells, glucocorticoids inhibit the 
transcription factors that regulate the inflammatory cytokines and the production of 
inflammatory lipids. (12) 
The GR can also induce the expression of anti-inflammatory proteins, such as annexin-1 (Anx-
1), MAPK phosphatase-1 (MPK-1) and glucocorticoid-induced leucine zipper (GILZ), by a 
transactivation mechanism and through post-genomic effects.(12) There is evidence that 
glucocorticoids can also have nongenomic actions capable of producing additional effects in 
various tissues. At a central level, excessive corticosteroids synthesis can lead to euphoria and 
psychosis, while deficiency can result in apathy, lethargy and depression. These effects may 
happen in the first minutes of exposure, however the process is not yet quite understood. (4)  
 
Bárbara Viana | Use of topical corticosteroids in oral pathology – a review 
8 
 
 
 
Figure 3:Schematic illustration of the glucocorticoids anti-inflammatory effects (7, 12) 
 
So, in resume, glucocorticoids have the capacity of inhibit vascular dilation, liquid transudation, 
edema formation, decrease cell exudates, reduce fibrin deposit in the inflamed area, among 
others. The principal mechanisms responsible for these actions consist in the inhibition of 
leukocyte chemotaxis, inhibition of fibroblast function and endothelial cells, reduction of a 
variety of chemical inflammation mediators, and antiproliferative activity. (5, 19)  
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Indications 
 
Glucocorticoids have many indications due to their various properties such us being anti-
inflammatory, immunosuppressive, antiproliferative, analgesic and antiemetic agents. (11, 13, 19)  
 
 
Table I: Resume of the glucocorticoid’s indications based on their properties (11, 13, 19) 
Properties Applications 
Anti-inflammatory  Imuno-inflammatory conditions such as asthma, 
rheumatoid arthritis, lupus erythematosus, lichen 
planus, pemphigus, pemphigoid, recurrent aphthous  
Immunosuppressive/Imunnomodelatory Organ transplant recipients to prevent graft rejection, 
modulation of severe allergic reactions, autoimmune 
flare-ups 
Antiproliferative Hematologic malignances and as a  complementary 
medication in certain chemotherapic treatments   
Analgesic Adjuvant analgesic for cancer pain 
Antiemetics Chemotherapy-induced and postoperative nausea 
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Side effects and contraindications 
 
Although glucocorticoids have a wide application in distinct pathological conditions, relevant 
side effects are common and potentially problematic, especially with prolonged use. (4, 8, 20) 
Studies show that adverse effects occur in up to 90% of the patients who take glucocorticoids for 
more than 60 days, even if it is a low dosage, like less than 7.5mg/d, while short term use 
(described by some authors as 1 week) is relatively safe. (4, 8)  
Some of the adverse effects are: the development of diabetes mellitus, hypertension, gastritis, 
gastrointestinal haemorrhage, peptic ulceration, osteoporosis, weight gain, dyslipidemia, 
cataracts, Cushing syndrome, adrenal suppression (Addison disease) skin changes, muscle 
weakness, among others, due to their effects on systemic energy balance. Further, psychiatric 
side effects, such as mood disorders, anxiety, delirium, panic disorder, have also been described. 
(8, 20-22)  
Osteoporosis and osteopenia are due to the inhibition of calcium absorption in the 
gastrointestinal tract and increased bone resorption. For long term steroid therapy, when the 
potential risk of bone complication is expected, the prescription of calcium supplements with 
vitamin D to doses ≥ 5 mg / day, and bisphosphonates, if indicated by densitometry, could be 
considered. Bisphosphonates have the ability to prevent osteoclastic bone resorption, however, 
these are also associated with atypical fractures and osteonecrosis of the jaw; being the risk is 
higher after the administration of endovenous bisphosphonates. (8, 22, 23) However, calcium and 
vitamin D are not enough to prevent the bone loss attained with long term steroid therapy. (22) 
Cushing’s syndrome is a pathology caused due to chronic exposure to excess cortisol. It’s 
clinical presentation is related to the extend and duration of the excess, however some signs and 
symptoms are unmistakable like muscle wikness, increased fat in the abdomen, torso and face 
and wide purple striae.(24) Adrenal suppression usually goes “hand in hand” with the exogenous 
Cushing syndrome. Supraphysiologc or prolonged doses can lead to the suppression of the 
endogenous cortisol production, resulting in subsequent atrophy of the adrenal cortex.(21) 
Cushing’s syndrome and adrenal suppression have been observed not only in patients taking oral 
glucocorticoids, but also with intra-articular, epidural, inhaled, ocular, and topic preparations. In 
Cushing’s syndrome, it’s possible to identify signs and symptoms of mineralocorticoid excess, 
since endogenous glucocorticoids also act on mineralocorticoid receptors. (8) 
Addison disease is a rare pathology also known as primary adrenal insufficiency, which in most 
cases is caused by auto-immune destruction of the adrenal cortex. (25) 
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Addison disease can be directly induced by exogenous glucocorticoids, through negative 
feedback of the HPA axis. (8) 
The risk for cardiovascular events (e.g. heart failure, ischemic heart disease) is increased in 
patients under GC therapy, due to potential development of hypertension, dyslipidemia, diabetes, 
among others. (22, 23) 
Glucocorticoids have immunosuppressive effects that are capable of increasing host 
susceptibility to viral, bacterial, fungal, and parasitic infections; these, if present, constitute an 
absolute contraindication for the use of glucocorticoids. (23, 26)  
There has been a concern regarding glucocorticoids association with immune-related cancers. 
Some studies show a possible association of squamous cell carcinoma and bladder cancer with 
GC use. (23) 
Other alterations, such as avascular necrosis can be a side effect of glucocorticoids’ therapy, 
particularly identified within the femoral head, by a mechanism not fully understood yet. (22) 
Relative contraindications to the use of glucocorticoids include heart and kidney diseases, 
osteoporosis, diabetes, hypertension, peptic ulceration, among others, once these can potentiate 
the side effects of the medication itself, leading to life threatening events. (4, 22) Pregnancy and 
lactation are also relative contraindications for the glucocorticoid therapy. Some studies show 
that systemic glucocorticoids have a significantly increased risk of oral cleft development with 
first-trimester exposure. (3)  
To minimize systemic side effects, the use of alternative ways of administration, the use of the 
lowest dosage with therapeutic effects, and the use within the least amount of time, are 
recommended strategies. (19, 23) Careful monitoring and preventive strategies may also minimize 
side effects. (22) 
Given the effects that glucocorticoids may have, especially in the HPA axis, one must be careful 
when stopping the administration. Low doses administered for a short period of time can be 
discontinued without tapering; higher doses and/or long tern therapies may need tapering, which 
should be based upon clinical conditions (for example: established HPA axis dysfunction, 
patients under stress, etc.). (8, 27) 
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Interactions with other drugs 
 
Patients with higher risk of drug interactions are infants, children and elderly, those with 
multiple diseases, those who are on multiple drug therapy and those with hepatic or renal 
disease.(27) 
The major interactions of glucocorticoids with other drugs are the ones that either inhibit (such 
as rifampicin) or induce (such as cyclosporine) their metabolism. It´s particular important to be 
careful when prescribing drugs with a narrow therapeutic window, such as: warfarin, 
cyclosporine, doxepin, digoxin, theophylline and methotrexate, since in this cases, the amount of 
drug needed to produce the desired therapeutic effect is very close to the dose that can be toxic. 
For instance, the concomitant therapy of GCs with methotrexate is associated with increased 
hepatotoxicity.(27) 
Some studies show a negative correlation between steroid treatment and the concomitant use of 
antibacterial agents, as the presence of steroids causes a biofilm conversion, which correlates 
with increased colonization persistence and enhanced antibiotic tolerance. (28) 
The use of glucocorticoids and non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen) 
seems to have a synergic effect regarding the increase on the risk of peptic ulceration and 
gastrointestinal bleeding. Therefore, caution should be exercised when using this combination. 
(22, 29, 30) Some studies have also reported that the use of COX-2 inhibitors and glucocorticoids 
could increase the prevalence of gastrointestinal events.(29) 
Antifungals like ketoconazole and itraconazole increase the plasma levels of methylprednisolone 
and dexamethasone. (27) 
Macrolides are responsible for increasing therapeutic and adverse effects of methylprednisolone. 
(27) 
Glucocorticoids may antagonize the medication used in hypertension or diabetes, therefore 
destabilizing patients that were otherwise controlled. (27) 
As glucocorticoids have the capacity of suppressing the immune system, live vaccines should not 
be given at the same time. (27) 
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Use in Dental Practice 
 
Regarding dental practice, the use of corticosteroid therapy, for a long period of time, it is not 
very common, which carries a lower risk for the complications described with chronic use. (4)   
Systemic glucocorticoids are sometimes used in surgical procedures involving osteotomy, where 
we can expect an exaggerated inflammatory response, to better control inflammation and reduce 
edema formation. (2, 5) For instance, third molar extraction originates injury to the surrounding 
tissues, associated with pain, acute inflammation, and trismus, being corticosteroid therapy 
generally considered. (5) Additionally, these drugs are routinely used in severe lesions of the oral 
mucosa (which will permit a quicker resolution of the symptoms).  
Prednisolone is the most common glucocorticoid prescribed for chronic conditions. It needs to be 
biotransformed to the active form, being it the reason why it is only available for oral use (allows 
first-pass metabolism during absorption). (4) 
 
 
Topic glucocorticoids 
 
Topic glucocorticoids are one of the most prescribed drugs in oral pathology for treating atrophic 
erosive lesions that affect the oral mucosa. (2) Broadly, clobetasol propionate, fluocinonide and 
triamcinolone acetonide are the most commonly used GCs. (2) Attention should be given to the 
fact that the use of topical glucocorticoids is set on the symptomatic treatment, and not on the 
curative approach of oral conditions, being the discontinuing of the GCs use, often followed by 
recurrence of the symptoms of the disease.(2) 
Topic use is associated with a strong local anti-inflammatory and immunosuppressive activity, 
being well tolerated. (1, 2) Nevertheless, oral local adverse reactions include secondary candidosis, 
mucosal atrophy, delayed cicatrization, refractory response, hypogeusia, burning mouth, 
hypersensitive reactions. (1, 2) The refractory response can occur due to different reasons, such as 
poor patient compliance, bad instructions and patient use or inappropriate application. (1)  
Furthermore, systemic absorption of topical applications continues to bring some concerns, as 
absorption through to oral mucosa is verified. However, clinical experience and most studies 
have shown no clinical significance of this situation in the majority of cases. (1) 
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Still, exceptions arise and systemic adverse effects, such as inhibition of the hypothalamic-
pituitary adrenal axis and secondary adrenal insufficiency, nausea ,among others, were verified 
in a small number of patients.(1, 2)  
Following the rule, glucocorticoids should be avoided in growing children (because of their 
interference in the development), but if absolutely necessary, the intermittent use of medium 
potency glucocorticoids is often the choice, because it can thus reduce the development of 
adverse effects. (1) 
Topical glucocorticoids appear to be safe during pregnancy; however, their use should be further 
investigated due to the absence of data. Nevertheless, mild to moderate-potency topical 
glucocorticoids should be preferred, for the shortest time possible. (31)  
The short time use (2-6 days) is indicated in diseases which have the natural tendency to 
spontaneous resolution, reducing its duration, and symptoms, as well. (2) The prolonged use is 
eligible to chronic or very recurrent erosive lesions, like oral lichen planus (OLP), mucous 
membrane pemphigoid and some forms of complex recurrent aphthous stomatitis.(2)  
When treating mucosal lesions, topical ointments or rinses are normally preferred. (4)  
However the efficacy of the treatment depends on the time that the glucocorticoid is in contact 
with the lesion; in the oral mucosa due to saliva, movement of the tongue, among other reasons, 
it’s difficult to keep the ointment for the necessary amount of time. For this reason, adhesive 
ointments are often used in customized trays, aiming the improvement of the treatment. (2) To 
create an adhesive ointment, adhesive pastes for dentures can be used, given that studies support 
its good adherent qualities and clinical success. This technique should be used when treating 
small, isolated lesion or few lesions easily accessible. It’s difficult to apply the medication in 
deep or large lesions and be certain that the drug is equally spread. (2) If the lesions are situated 
on the gums or palate, the medication can be applied with the help of a customized tray (or in 
denture if the patient is edentulous), allowing perfect control of the amount of time that the drug 
is in contact with the lesions. (2)  
Glucocorticoids can also be applied in aqueous solutions. This has great advantages like the 
capacity of controlling perfectly the time of exposition to the lesions, contact with all lesions 
regardless if they are large or deep and easier manipulation. However, it has also some 
disadvantages such as all mucosa (healthy or not) comes in contact with the medication, 
increasing systemic absorption and the risk of involuntary ingestion. (2) 
Literature gives greater attention to clobetasol propionate, fluocinonide and triamcinolone 
acetonide, whose principal characteristics are described in the table below (2):  
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Table II: Summary of principal characteristics of the most commonly used topical 
glucocorticoids prescribed in oral pathology (2) 
 
Potency Recommended Concentration Applications  
Clobetasol 
propionate 
High 0,025% - 0,05% 
2-3 x/day  
3-5 min 
Fluocinonide Moderate-high 0,025% - 0,05%  
5-10 x/day 
3-5 min 
Triamcinolone 
acetonide 
Average  0,05% - 0,5% 
3-10 x/day 
3-5 min 
 
 
Clobetasol propionate has the capacity to control rapidly the mucosal lesions, with a low number 
of applications each day, allowing longer lesion-free periods after the discontinuing of the 
treatment. Also, it can be used in severe erosive lesions with efficacy, allowing for an adequate 
control with topic administration.(2) 
Fluocinonide is less effective in pain controlling than clobetasol. (2) 
Triamcinolone acetonide is also very commonly prescribed within the management of oral 
mucosa lesions. However, some authors disclose its limitations, since it needs several 
applications during the day, which is a major inconvenience to the patient and can lead to failure 
of treatment efficacy.(2) 
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Oral Pathology 
 
Oral Lichen Planus 
 
Oral lichen planus (OLP) is a chronic inflammatory, mucocutaneous disease, associated with 
cell-mediated immunological dysfunction, that affects the oral mucosa, skin, genital mucosa, 
scalp and nails. (32-34) Its etiology is yet unknown. (33)  This disease is most seen in middle-aged 
patients, primarily in women. (32) Commonly, it affects the oral mucosa without the presence of 
skin lesions.(34) 
OLP is described in six types of clinical variants: reticular, popular, plaque-like, erosive, atrophic 
and bullous. It is possible to have multiple or coexistent forms, in the same patient. Clinically it 
may exhibit in various manifestations such as white striations (known as Wickham’s striae, 
which are a characteristic feature), white papules, white plaque (this form may be difficult to 
differentiate from leucoplakia), erythema, erosion or blisters (however this is rare). (33, 34) OLP 
generally occurs in the buccal mucosa, tongue, gingiva, mucobuccal area, while mucosa of palate 
and floor of the mouth are rarely affected (32, 35) Its most common form is the reticular lesion, 
followed by erosive, atrophic and plaque types.(32, 35) Reticular form expresses the typical 
Wickham’s striae and is often asymptomatic; wheatear it should be controlled (1 year follow up), 
since it can evolve to a symptomatic form: ulcerative (erosive) or atrophic. (32-34) These forms 
can cause burning sensations and severe pain, associated with a risk of malignant transformation, 
particularly lesions of the tongue.(32) 
The classic histologic characteristics are band-like dense inflammatory infiltrate of T 
lymphocytes, hyperparakeratosis with thickening of the granular cell layer, liquefactive 
degeneration of basal keratinocytes, Civatte bodies, saw-tooth appearance of rete ridges and 
normal maturation epithelium. (33-37)  
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Figure 4: Presence of oral lichen planus on the oral mucosa (right cheek). Courtesy of Prof. Dr. Otília Lopes 
 
 
 
 
 
 
 
 
 
 
Figure 5: Presence of erosive oral lichen planus on the oral mucosa (left cheek). Courtesy of Prof. Dr. Otília 
Lopes 
 
Treatment 
 
Various treatments have been used to manage the symptomatic oral lichen planus, with variable 
results, such as: topical retinoids, topical calcineurin inhibitors (like tracolimus, pimecrolimus), 
photochemotherapy, photodynamic therapy, among others. (33, 35) 
Glucocorticoids are the most used due to their activity in suppressing cell mediated immune 
activity, more specifically, topical glucocorticoids are the first-line therapy for mucosal erosive 
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lichen planus; they are able to improve some of the components of the lesion, however the 
underlying and persistent immune mechanisms remain active. (2, 36) Specific protocols can be 
used for individual patients based on their lesion characteristics. (2) 
Systemic glucocorticoids, like prednisolone, are used only in severe, resistant, widespread oral 
lichen planus. (34, 36) 
 
Table III: Evidence basis for the value of topical glucocorticoids in the treatment of Oral 
Lichen Planus (Adapted from Al-Hashimi et al, 2007) (34, 38, 39) 
Topical glucocorticoid Form of administration Indication 
 
Clobetasol propionate 0.025% 
 
Ointment – applied 2X/day for 
the first month, then 1X/day for 
the second month 
 
 
Treatment of choice for symptomatic 
atrophic/erosive OLP 
 
 
Clobetasol propionate 0.05% 
 
 
Ointment – gingival trays for at 
least ½ hour a day, 2X/day for 6 
weeks 
 
Mixed atrophic-erosive, hyperkeratosic 
OLP with strong gingival involvement 
 
Clobetasol propionate 0.05% 
 
 
 
Mouthwash – 2 to 3X/day 
Severe erosive oral lichen planus lesions 
 
Triamcinolone acetonide 0.1% 
 
Mixed with orabase – applied 3 
times daily, until symptoms 
improve 
 
 
Treatment of choice for symptomatic 
atrophic/erosive OLP 
 
 
Triamcinolone acetonide 0.1% 
 
 
Mouthwash – rinse for 4 weeks 
 
Generalized lesions of symptomatic OLP 
 
Fluocinolone acetonide 0.1% 
 
Orabase – applied 4X/day for 1 
month 
 
 
Chronic symptomatic atrophic/erosive 
OLP 
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Studies show that when using triamcinolone acetonide at 0.0025%, 25% of the patients with oral 
lichen planus achieve complete resolution of the lesions.(2) Other study reported that the use of 
fluocinolone acetonide should be preferred because will be no permanent adrenal cortical 
suppression and it’s more effective that triamcinolone acetonide. (33) 
Other topic glucocorticoids that can be used are: fluticasone propionate, betamethasone sodium 
phosphate and momethasone. These are less explored; however some studies reported very good 
results with momethasone with minimal side effects.(2) 
Oral lichen planus may have an unpredictable response to the glucocorticoids, so it’s possible 
that some times, the white lesions can become even whiter. There are some areas that respond 
worse to the treatment, like the mucosal atrophy; even after the treatment these areas can still 
have atrophy characteristics.(2) 
It’s very common to have a secondary candidiasis during the treatment (it’s the most frequent of 
the side effects), so prescribing Nystatin either in cream or aqueous from is an option to reduce 
it. (1, 2, 34) 
Despite the verified evidence, there is a need for more studies to standardize the methodology for 
the treatment of OLP with both topical and systemic glucocorticoids. 
 
Pemphigus 
 
Pemphigus is a rare, serious autoimmune disease that causes blistering of the skin and oral 
cavity. It left untreated, it is often fatal. (40, 41) Two basic forms of this condition are 
acknowledged: pemphigus vulgaris and pemphigus foliaceous, although oral lesions do not occur 
in pemphigus foliaceous. Pemphigus vulgaris affects the basal-cell layer and is associated with 
auto-antibodies to desmoglein 3 (which is a keratinocyte cell-surface adhesion molecule) and it’ 
is most commonly diagnosed in the fourth to sixth decades.(41) 
Pemphigus vulgaris is characterized clinically by oral pain, presence of erosions and superficial 
ulcerations at different sites of the oral mucosa, preferably in oral and labial mucosa, ventral 
surface of the tongue, palate and gums (can also be recognized as gingivitis descamativa). Rarely 
vesicles or intraoral bubbles are identified, possibly by the friability of the lesions. A bubble can 
be produced in the mucosa or normal-looking skin if pressure is imposed on its surface. This is 
called Nikolsky positive sign. (40, 41) 
To diagnose pemphigus vulgaris, we can resort to its clinic, histopathological and immunological 
characteristics. (40)  
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Its etiopathogenesis is related to an immune response, wherein auto-antibodies are directed into 
keratinocytes antigens, which results in the separation of these cells from one another (a process 
known as acantholysis), which in turn originates bulla, as described in figure 3. (40, 41) 
 
 
 
 
Figure 6: Diagram representing the process of acantholysis resulting from the attack of the auto-antibodies to 
the antigens of keratinocytes.(41) 
 
The most relevant histological characteristics of oral pemphigus vulgaris are: presence of 
intraepithelial cleft located above the basal-cell layer, acantholysis, Tzanck cells (round cells 
with acantholysis present in area) and a mild to moderate chronic inflammatory infiltrate in the 
underlying connective tissue. (40, 41) 
 
 
 
 
 
Auto-antibodies directed 
against antigens on the surface 
of keratinocytes 
Dissolution of the intercellular 
substance 
Separation of desmossomes 
Formation of a cleft within the 
epidermis 
Enlarges in to a bulla 
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Treatment 
 
The treatment can be divided in three phases: control, consolidation, maintenance. (41) The 
control phase is the period in which the intensity of therapy is higher. The aim is to inhibit the 
formation of new lesions and start the healing process. If the right dose of medication is given, 
an adequate treatment response can be verified in 2 weeks. The consolidation phase is the period 
in which the intensity of the therapy needed to control the disease is maintained until 80% of 
previous lesions have healed. At last, the maintenance phase is the period in which the intensity 
of the therapy is gradually reduced. (41)   
Oral lesions can be treated with potent topical glucocorticoids, such as clobetasol propionate 
0.05%, mixed with adhesive paste, fluocinonide 0.05% and dexamethasone elixir, 2 to 3 
applications a day for 3 to 5 minutes as described in literature. (2) For gums and hard palate, 
customized acrylic trays can be used. Similar results are achieved with intralesional injections of 
triamcinolone acetonide diluted to 10mg/mL. (41, 42)  
Systemic therapy for pemphigus may be administered orally. The most used glucocorticoid is 
prednisolone, and the administration protocol depends on the severity of the disease. The initial 
recommended dose of prednisone is 0.5–2 mg/kg Depending on the response, the dose can be 
decreased slowly to the minimum therapeutic dose, taken once a day in the morning to minimize 
side effects. (40) If with the topical treatment, new lesions still form, it can be administered a low 
dose of prednisolone: 20 to 40mg /day; if the patient doesn’t respond to the treatment, we can 
increase the dose to 70 to 90 mg/day, which is a moderately high dose.(41)  
There is not much information about doses and posology to use in dentistry, especially for the 
topical treatment so more studies are needed.  
 
Bullous pemphigoid 
 
Bullous pemphigoid is a chronic autoimmune disease that affects most the elderly after the 
seventh decade.(43) It is characterized by an autoimmunity activation (as pemphigus and other 
autoimmune diseases) due to the loss of self-tolerance in T and B lymphocytes, more 
specifically, an auto-antibody response against structural components of hemidesmossomes, 
resulting in sub-epidermal blistering. (43, 44) Bullous pemphigoid may have spontaneous 
exacerbation and remission phases.(43) Generally, it is characterized by a nonbullous phase, in 
which the manifestations are nonspecific: pruritus, excoriated, eczematous, papular, and or fixed 
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urticarial-like lesions. These can persist for several months or be the only sign of this pathology. 
The bullous phase is characterized by large and tense blisters with round or oval shape. Oral 
mucosa is involved in 10% to 25% of the patients.(44)  
The bullous pemphigoid etiopathogenesis is not fully understood yet, but it is thought that some 
factors may contribute, such as drug intake, physical agents, viral infections and diet.(44) 
The mechanism responsible for the blisters formation is resumed in the diagram below (see 
figure 4).(44)  
The principal histological characteristics are sub-epidermal blister with superficial dermal 
inflammation (presence of lymphocytes, histiocytes and eosinophils). (44) 
 
 
 
Figure 7: Diagram explaining the process of auto-immune activation that leads to the blister formation in 
Bullous pemphigoid.(44) 
 
 
 
 
Proteolytic events and blister formation 
The loss of cell-matrix adhesion within the dermal-epidermal junction is directly mediated by the 
proteinases released by the inflammatoy cells. 
Accumulation of eosinophils, neutrophils and their proteolytic enzymes 
After the process  of degranulation, mast cells release mediators like leukotriens, platelet-activating factor, 
TNF-α, among others, which provides the recruitment of neutrophils and eosinophils to the target tissue.  
Mast cell degranulation 
Mast cell degranulation can be induced by complement activation-derived fragments such as C3a and C5a, 
and even  by IgE (present in high levels on almost all patients). 
Complement activation 
The binding of the auto-antibodies to their target activates the complement. By direct immunofluorescence 
Protein C3, among others, can be detected in perilesional skin/mucosa. 
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Figure 8: Presence of bullous pemphigoid lesions on the oral mucosa. Courtesy of Prof. Dr. Otília Lopes 
 
 
Treatment  
 
The management of bullous pemphigoid depends on its multifactorial pathogenesis; however, 
systemic glucocorticoids are still the first choice for the treatment of this disease. A dose of 
prednisolone 0.75mg to 1.00mg/Kg/day or less should be the necessary to maintain the disease 
controlled. Once the blisters stop, its development and erythema has reduced, tapering of 
prednisolone is recommended. This is usually achieved by the end of second week of therapy. 
The use of topical therapy alone is a valid alternative to the systemic use. (43) There are no 
guidelines available for the dental management of this condition, only for dermatologic 
management, and as absorption by the skin is not the same as the one as in the oral mucosa 
(since the latter is more irrigated and thinner, grating the absorption faster and more complete) 
and also by the fact that the lesions do not have the same characteristics. In this way, the 
corticosteroid dosage may be different, so more studies are required. 
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Recurrent aphthous stomatitis 
 
The recurrent aphthous stomatitis is a chronic inflammatory pathology very common in the oral 
mucosa. (45, 46) Its most characteristic symptom is the recurrent onset of single or multiple 
erosions and ulcers; these appear mainly on unattached oral mucosa of the lips, cheeks and 
tongue, however it is possible to be observed on keratinized palatal and gingiva mucosa.(45)  
The recurrent aphthous stomatitis may be divided in three forms: recurrent aphthous stomatitis 
minor, major and the herpetiform. (45) The minor form is the most usual. The second one it’s 
frequently found in patients infected with HIV. (46) In the last one, ulcers may coalesce to form 
larger ulcers with marked erythema.(46)The principal characteristics of these conditions are 
described in the table below: 
 
Table IV: Principal clinical characteristics of the 3 forms of recurrent aphthous stomatitis 
(RAS) (Adapted from Zuzzana S. et al, 2014) (45, 46)  
 
Type of 
RAS 
Size 
(mm) 
Number of 
lesions 
Depth Scar 
Duration 
(days) 
Peek onset (age) Localization 
Minor 5-10 <10 Shallow No 10-14 2nd decade life 
Non keratinized oral mucosa; more 
common: lips, buccal regions, tongue 
margins 
Major >10 1-3 Deep Yes >14 
1st and 2nd decades 
of life  
Kenatinized and non-keratinized oral 
mucosa; more common: soft palate, lips, 
tongue, palatal fauces 
Herpetiform <5 >10 Shallow No 10-14 3rd decades of life 
Non keratinized oral mucosa; more 
common: floor of the mouth, ventral 
surface of the tongue 
 
 
Its pathogenesis is still not known, however both local and systemic factors can be associated 
with it; it’s also thought that an immune-mediated reaction (lesions arise as a consequence of 
immunologically mediated cytotoxicity of epithelial cells) exists. (45, 46) 
Diagnose is made after clinical exam, with detailed history and examination of the ulcers. (46) 
Histological characteristics include massive leukocytic infiltration (that can be different 
according with the severity and duration of the disease); before the ulcer formation, monocytes 
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and lymphocytes (principally T type) infiltration, with single mast and plasmatic cells under the 
basal cell layer. After the ulcer formation, polynuclear leukocytes recruitment occurs to the 
center of the ulcer, with mononuclear cell infiltration on the lesion border. (46) 
 
 
 
 
 
 
 
 
 
 
         Figure 9: Presence of major ulcer on the lips. Courtesy of Prof. Dr. Otília Lopes 
 
Treatment 
 
The principal aim of the treatment is to decrease the symptoms, reduce ulcer number and 
increase the disease-free period.(47) 
Topical medication is often the first choice, such as  triamcinolone acetonide (orabase), 
intralesional injections), clobetasol propionate (orabase), fluocinonide ointment (orabase), (see 
table IV) and can often include the use of a chlorhexidine mouthwash (without alcohol base) or 
dexamethasone 0.05 mg ⁄ 5 ml (rinse and spit three times per day). The elixirs are most used 
when multiple ulcers are localized in soft palate or oropharynges, as well as for multiple and 
diffuse ulcers.(47-49) See table IV. 
Systemic treatment is recommended for severe, refractory, constantly recurring ulcerations.(46) A 
short course of systemic glucocorticoid therapy (oral prednisolone) may be necessary, but it 
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shouldn’t exceed more than 50 mg/day (preferably in the morning) for 5 days. Some studies refer 
we should start with 25mg/day. Tapering may be necessary. (48, 49) 
 
Table V: Indications of topical glucocorticoids in the treatment of Recurrent Aphthous 
Stomatitis (48, 49) 
Topical glucocorticoid Form of administration Indication 
 
Triamcinolone acetonide  
0.05-0.5% 
 
 
Pomade orabase – 3 to 
10X/day for 3 to 5 minutes 
 
Localized ulcers, small and mild 
erosive lesions  
 
Fluocinolone acetonide 
0.025-0.05% 
 
 
Pomade orabase – 5 to 
10X/day for 3 to 5 minutes 
 
Localized ulcers, however more 
aggressive  
 
Clobetasol propionate 
0.025% 
 
 
Pomade orabase  - 2 to 
3X/day for 3 to 5 minutes 
 
 
Localized ulcers with moderate or 
severe presentations 
 
Triamcinolone acetonide 
Fluocinolone acetonide 
Clobetasol propionate 
 
 
Rinses/Mouthwashes forms – 
3 to 4X/ day  
20-30 minutes without eating 
or drinking 
 
 
 
Multiple, diffuse oral ulcers  
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Conclusion 
 
Since its discovery, glucocorticoids have been widely used for the management of distinct 
conditions, being applied for the management of inflammatory disorders, autoimmune diseases, 
antenatal use for preterm birth, and hematological cancers, among others. However, when 
associated with treatments for long periods of time (particularly when using systemic 
glucocorticoids) a high incidence of adverse effects is verified. In dentistry, corticosteroids are 
commonly used for shorter periods of time and thus, fewer risks are broadly associated. 
In the practice of dentistry, they are widely used in inflammatory diseases with an autoimmune 
nature, and to control inflammation. Systemic corticosteroids are frequently used to control 
inflammation in more invasive surgical procedures, as those including osteotomy. They can also 
be used as adjuvants in topical medication to control more severe lesions of the oral mucosa, 
wither erosive or refractory in nature.  
On the other hand, topical corticosteroid therapy is commonly used for the management and 
control of immune-inflammatory conditions of the oral mucosa, being acetonide triamcinolone, 
fluocinolone acetonide and clobetasol propionate, the most commonly drugs. These can be used 
in different application forms: customized trays, adhesive (orabase) ointments, gels, intralesional 
injections and elixirs, being selected in accordance with the lesions characteristics. 
Guidelines for treatment / maintenance of distinct conditions with topical corticosteroid therapy 
were found available, especially regarding oral lichen plan and recurrent aphthous stomatitis 
conditions. However, less is known regarding therapeutic management of pemphigus vulgaris or 
bullous pemphigoid, since the majority of the literature refers to dermatology guidelines. As 
absorption by the skin is not as the one in oral mucosa, more studies should be conducted in 
these areas in order to disclose therapeutic guidelines adequately focused on the oral 
management of these conditions.    
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